Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis
Filetype[PDF-117.55 KB]


Details:
  • Alternative Title:
    MMWR Morb Mortal Wkly Rep
  • Personal Author:
    Nelson, Noele P.
  • Corporate Authors:
    National Center for HIV, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis.
  • Description:
    GamaSTAN S/D (Grifols Therapeutics, Inc., Research Triangle Park, North Carolina) is a sterile, preservative-free solution of immune globulin (IG) for intramuscular administration and is used for prophylaxis against disease caused by infection with hepatitis A, measles, varicella, and rubella viruses (1). GamaSTAN S/D is the only IG product approved by the Food and Drug Administration for hepatitis A virus (HAV) prophylaxis. In July 2017, GamaSTAN S/D prescribing information was updated with changes to the dosing instructions for hepatitis A preexposure and postexposure prophylaxis indications. These changes were made because of concerns about decreased HAV immunoglobulin G antibody (anti-HAV IgG) potency, likely resulting from decreasing prevalence of previous HAV infection among plasma donors, leading to declining anti-HAV antibody levels in donor plasma (2). No changes in dosing instructions were made for measles, varicella, or rubella preexposure or postexposure prophylaxis.

  • Subject:
  • Pubmed ID:
    28910270
  • Pubmed Central ID:
    PMC5657912
  • Document Type:
    Journal Article
  • Collection(s):
    Morbidity and Mortality Weekly Report (MMWR)
  • Main Document Checksum:
No Related Documents.
You May Also Like:
  1. Considerations for use of hepatitis A vaccines for post-exposure prophylaxis and international travel
    Personal Author:
    Nelson, Noele
    Corporate Authors:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). United States. Advisory Committee on Immunization Practices. Hepatitis Vaccines Work Group..
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2018 February 21-22 : Atlanta, GA)
    Published Date:
    4/9/18
    Series:
    ACIP meeting Hepatitis Vaccines
    Description:
    Presentations February 2018 Day 1Publication date from document properties.Hepatitis-04a-Nelson-508.pdf
    File Type:
    Filetype[PDF - 714.17 KB]
  2. MMWR. Morbidity and mortality weekly report, Vol. 66, no. 36, September 15, 2017
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    September 15, 2017
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 66, no. 36
    File Type:
    Filetype[PDF - 611.82 KB]
  3. Update: Recommendations of the Advisory Committee on Immunization practices for use of hepatitis A vaccine for postexposure prophylaxis and for preexposure prophylaxis for international travel
    Personal Author:
    Nelson, Noele P.; Link-Gelles, Ruth; Hofmeister, Megan G.; Romero, José R.; Moore, Kelly L.; Ward, John W.; Schillie, Sarah F.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis..
    Published Date:
    Nov 02 2018
    Source:
    MMWR Morb Mortal Wkly Rep. 67(43):1216-1220
    Description:
    Postexposure prophylaxis (PEP) with hepatitis A (HepA) vaccine or immune globulin (IG) effectively prevents infection with hepatitis A virus (HAV) when administered within 2 weeks of exposure. Preexposure prophylaxis against HAV infection through the...
    File Type:
    Filetype[PDF - 109.44 KB]
  4. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel
    Personal Author:
    Nelson NP, Link-Gelles R, Hofmeister MG, et al.
    Corporate Authors:
    Centers for Disease Control and Prevention (U.S.)
    Published Date:
    November 2, 2018
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 43
    Description:
    Postexposure prophylaxis (PEP) with hepatitis A (HepA)
    Status:
    current
    File Type:
    Filetype[PDF - 114.31 KB]
  5. Supplementary text 1. Provider Guidance on Risk Assessment and Clinical Decision-making for Hepatitis A Postexposure Prophylaxis. Supplements: Update: Recommendations of the Advisory Committee on Immunization Practices for use of Hepatitis A vaccine for post-exposure prophylaxis and for international travel
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    November 2, 2018
    Source:
    Update: Recommendations of the Advisory Committee on Immunization Practices for use of Hepatitis A vaccine for post-exposure prophylaxis and for international travel. MMWR. Morbidity and mortality weekly report ; v. 67, no. 43, p.
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 43, p.
    File Type:
    Filetype[PDF - 193.35 KB]